Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Clinical Care/Education/Nutrition

Antiatherogenic Effect of Pioglitazone in Type 2 Diabetic Patients Irrespective of the Responsiveness to Its Antidiabetic Effect

  1. Noriko Satoh, MD, PHD1,
  2. Yoshihiro Ogawa, MD, PHD2,
  3. Takeshi Usui, MD, PHD1,
  4. Tetsuya Tagami, MD, PHD1,
  5. Shigeo Kono, MD, PHD1,
  6. Hiroko Uesugi, MD, PHD3,
  7. Hiroyuki Sugiyama, MD, PHD3,
  8. Akira Sugawara, MD, PHD1,
  9. Kazunori Yamada, MD, PHD1,
  10. Akira Shimatsu, MD, PHD1,
  11. Hideshi Kuzuya, MD, PHD1 and
  12. Kazuwa Nakao, MD, PHD2
  1. 1Diabetes Center and Clinical Research Institute of Kyoto National Hospital, Kyoto, Japan
  2. 2Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan
  3. 3Department of Internal Medicine, Saiseikai Noe Hospital, Osaka, Japan
  1. Address correspondence and reprint requests to Yoshihiro Ogawa, MD, PhD, Department of Molecular Medicine and Metabolism, Medical Research Institute, Tokyo Medical and Dental University, 2-3-10 Kanda-surugadai, Chiyoda-ku, Tokyo 101-0062, Japan. E-mail: ogawa.mmm{at}mri.tmd.ac.jp
Diabetes Care 2003 Sep; 26(9): 2493-2499. https://doi.org/10.2337/diacare.26.9.2493
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • Figure 1—
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1—

    A and B: Plasma CRP levels and PWV in the control and pioglitazone-treated groups before and at the end of this study. Each column and bar represents the mean ± SEM before (B) and after 3 months (A). **P < 0.01. C and D: Plasma CRP levels and PWV in the nonresponders and responders before and 3 months after treatment with pioglitazone. Each column and bar represents the mean ± SEM before (B) and after 3 months (A). *P < 0.05; **P < 0.01.

Tables

  • Figures
  • Table 1—

    Baseline characteristics of patients treated with or without pioglitazone

    VariablesControlPioglitazone
    n6670
    Sex (male/female)32/3432/38
    Age (years)59.3 ± 1.961.2 ± 1.3
    BMI (kg/m2)23.0 ± 0.523.4 ± 0.4
    SBP (mmHg)146 ± 2144 ± 2
    DBP (mmHg)82 ± 281 ± 2
    FPG (mmol/l)9.4 ± 0.39.6 ± 0.4
    HbA1c (%)8.0 ± 0.28.1 ± 0.1
    IRI (pmol/l)55.9 ± 4.1057.5 ± 3.96
    HOMA-IR3.30 ± 0.283.35 ± 0.29
    Total cholesterol (mmol/l)5.45 ± 0.165.46 ± 0.10
    LDL cholesterol (mmol/l)3.32 ± 0.113.30 ± 0.08
    HDL cholesterol (mmol/l)1.47 ± 0.101.44 ± 0.05
    Triglycerides (mmol/l)1.55 ± 0.041.56 ± 0.04
    Adiponectin (μg/ml)6.08 ± 0.426.03 ± 0.34
    Leptin (ng/ml)6.56 ± 0.456.52 ± 0.50
    Treatment of diabetes (n)
     Diet alone2828
     Diet + sulfonylureas3842
     Diet + metformin00
    Use of antihypertensive medications (n)
     ACE inhibitors or angiotensin II receptor antagonists00
     Other2227
    Use of lipid-lowering medications (n)
     Statins1913
     Fibrates31
     Other31
    • Data are means ± SEM. All group differences are nonsignificant.

  • Table 2—

    Results of 3-month additional treatment with pioglitazone in the study patients

    VariablesControl (n = 66)
    Pioglitazone (n = 70)
    Baseline3 monthsBaseline3 months
    BMI (kg/m2)23.0 ± 0.523.2 ± 0.523.4 ± 0.423.5 ± 0.4
    SBP (mmHg)146 ± 2146 ± 3144 ± 2145 ± 2
    DBP (mmHg)82 ± 282 ± 281 ± 281 ± 2
    FPG (mmol/l)9.4 ± 0.39.2 ± 0.39.6 ± 0.48.0 ± 0.3†§
    HbA1c (%)8.0 ± 0.27.9 ± 0.28.1 ± 0.17.1 ± 0.1†§
    IRI (pmol/l)55.9 ± 4.1054.9 ± 4.1057.5 ± 3.9651.7 ± 5.18
    HOMA-IR3.30 ± 0.283.20 ± 0.293.35 ± 0.292.25 ± 0.17†§
    Total cholesterol (mmol/l)5.45 ± 0.165.46 ± 0.175.46 ± 0.105.33 ± 0.10
    LDL cholesterol (mmol/l)3.32 ± 0.113.33 ± 0.123.30 ± 0.083.17 ± 0.08*
    HDL cholesterol (mmol/l)1.47 ± 0.101.43 ± 0.111.44 ± 0.051.47 ± 0.05
    Triglycerides (mmol/l)1.55 ± 0.041.57 ± 0.061.56 ± 0.041.50 ± 0.04
    Adiponectin (μg/ml)6.08 ± 0.426.06 ± 0.396.03 ± 0.347.82 ± 0.52†‡
    Leptin (ng/ml)6.56 ± 0.456.58 ± 0.456.52 ± 0.506.63 ± 0.46
    • Data are means ± SEM.

    • *

      ↵* P < 0.05,

    • †

      ↵† P < 0.01 vs. baseline values;

    • ‡

      ↵‡ P < 0.05,

    • §

      ↵§ P < 0.01 vs. control.

  • Table 3—

    Results of 3-month additional treatment with pioglitazone in the study patients divided into two subgroups

    VariablesNonresponders (n = 30)
    Responders (n = 40)
    Baseline3 monthsBaseline3 months
    Sex (male/female)12/1820/20
    Age (years)60.4 ± 2.161.8 ± 1.6
    BMI (kg/m2)22.7 ± 0.623.0 ± 0.6†23.9 ± 0.523.9 ± 0.5
    SBP (mmHg)144 ± 4143 ± 3144 ± 3146 ± 3
    DBP (mmHg)80 ± 280 ± 282 ± 283 ± 3
    FPG (mmol/l)9.4 ± 0.58.9 ± 0.49.7 ± 0.57.3 ± 0.4†‡
    HbA1c (%)7.8 ± 0.27.7 ± 0.28.3 ± 0.1‡6.8 ± 0.1†‡
    IRI (pmol/l)49.7 ± 4.9646.8 ± 4.7563.3 ± 5.7655.5 ± 8.42
    HOMA-IR2.96 ± 0.382.62 ± 0.31*3.65 ± 0.421.97 ± 0.16†‡
    Total cholesterol (mmol/l)5.40 ± 0.125.42 ± 0.115.51 ± 0.155.27 ± 0.16*
    LDL cholesterol (mmol/l)3.32 ± 0.093.27 ± 0.093.30 ± 0.113.09 ± 0.12*
    HDL cholesterol (mmol/l)1.37 ± 0.081.43 ± 0.081.50 ± 0.071.51 ± 0.07
    Triglycerides (mmol/l)1.54 ± 0.061.56 ± 0.051.57 ± 0.051.46 ± 0.06*
    Adiponectin (μg/ml)5.98 ± 0.527.48 ± 0.71†6.07 ± 0.468.08 ± 0.73†
    Leptin (ng/ml)6.16 ± 0.796.21 ± 0.776.79 ± 0.666.95 ± 0.56
    • Data are means ± SEM.

    • *

      ↵* P < 0.05,

    • †

      ↵† P < 0.01 vs. baseline values;

    • ‡

      ↵‡ P < 0.05 vs. nonresponders.

  • Table 4—

    ANCOVA models showing the differences associated with treatment with pioglitazone in CRP, PWV, and adiponectin

    Variables with pioglitazone treatmentCovariatesRegression coefficient (SEM)P value
    ΔCRPUnadjusted−0.018 (0.010)0.0262
    Adjusted for ΔHbA1c−0.041 (0.013)0.0015
     ΔHOMA-IR−0.027 (0.010)0.0117
     ΔBMI−0.042 (0.010)0.0001
    ΔPWVUnadjusted−51.94 (21.61)0.0180
    Adjusted for ΔHbA1c−50.64 (27.99)0.0423
     ΔHOMA-IR−47.03 (23.31)0.0463
     ΔsBP and ΔdBP−69.49 (26.87)0.0112
     ΔLDL−54.29 (21.89)0.0147
     ΔTriglycerides−49.89 (21.75)0.0238
     ΔCRP−34.56 (23.12)0.1381
     ΔAdiponectin−29.99 (22.47)0.1850
    ΔAdiponectinUnadjusted1.808 (0.474)0.0002
    Adjusted for ΔHbAA1c1.522 (0.616)0.0151
     ΔHOMA-IR0.547 (0.147)0.0003
    • Changes in variables are indicated by subtracting the pretreatment value from the post-treatment value.

PreviousNext
Back to top
Diabetes Care: 26 (9)

In this Issue

September 2003, 26(9)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Antiatherogenic Effect of Pioglitazone in Type 2 Diabetic Patients Irrespective of the Responsiveness to Its Antidiabetic Effect
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Antiatherogenic Effect of Pioglitazone in Type 2 Diabetic Patients Irrespective of the Responsiveness to Its Antidiabetic Effect
Noriko Satoh, Yoshihiro Ogawa, Takeshi Usui, Tetsuya Tagami, Shigeo Kono, Hiroko Uesugi, Hiroyuki Sugiyama, Akira Sugawara, Kazunori Yamada, Akira Shimatsu, Hideshi Kuzuya, Kazuwa Nakao
Diabetes Care Sep 2003, 26 (9) 2493-2499; DOI: 10.2337/diacare.26.9.2493

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Antiatherogenic Effect of Pioglitazone in Type 2 Diabetic Patients Irrespective of the Responsiveness to Its Antidiabetic Effect
Noriko Satoh, Yoshihiro Ogawa, Takeshi Usui, Tetsuya Tagami, Shigeo Kono, Hiroko Uesugi, Hiroyuki Sugiyama, Akira Sugawara, Kazunori Yamada, Akira Shimatsu, Hideshi Kuzuya, Kazuwa Nakao
Diabetes Care Sep 2003, 26 (9) 2493-2499; DOI: 10.2337/diacare.26.9.2493
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Increased Second Trimester Maternal Glucose Levels Are Related to Extremely Large-for-Gestational-Age Infants in Women With Type 1 Diabetes
  • An Evaluation of Methods of Assessing Impaired Awareness of Hypoglycemia in Type 1 Diabetes
  • Effects of Isoflavone Dietary Supplementation on Cardiovascular Risk Factors in Type 2 Diabetes
Show more Clinical Care/Education/Nutrition

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.